乐观
$4.12
情景价格
$1.220
+0.041 (+3.39%)收盘时
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.
Morgan Stanley
—
2026-09-25
Morgan Stanley
2026-09-25
目标价
—
Morgan Stanley
$3.2
2025-04-17
Morgan Stanley
2025-04-17
目标价
$3.2
Lake Street
$3.5
2024-08-07
Lake Street
2024-08-07
目标价
$3.5
Morgan Stanley
$3.5
2024-06-12
Morgan Stanley
2024-06-12
目标价
$3.5
Lake Street
$7
2024-06-12
Lake Street
2024-06-12
目标价
$7
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

PetMed Express Appoints New Independent Director

PetMed Express Enters $37M Sale-Leaseback Agreement for Headquarters

PetMed Express Receives Acquisition Proposal from SilverCape

SilverCape Revises Acquisition Proposal for PetMed Express

NASDAQ 100 Pre-Market Indicator Rises Significantly
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. It operates in the Consumer Non-Cyclicals sector (RETAIL-DRUG STORES AND PROPRIETARY STORES industry).
PetMed Express Inc is not a good buy right now. The current price is $1.22, and the stock has a negative year-to-date change of -63.03%. Additionally, the RSI is at 47.78, indicating that the stock is neither overbought nor oversold, which suggests a lack of strong momentum. The recent acquisition proposal at $3.00 per share indicates potential value, but the company's deteriorating financials, including a net income loss of $6.14 million in the last quarter, pose significant risks.
5 analysts cover PETS: 2 rate it Buy, 2 Hold and 1 Sell.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。